Salivary alpha-amylase (sAA) (sAA)

Salivary alpha-amylase, also known as ptyalin, is a calcium-dependent glycoside hydrolase enzyme primarily synthesized and secreted by the parotid glands [1]. Its fundamental biological role is the hydrolysis of alpha-1,4-glycosidic linkages in starch and glycogen, initiating the chemical digestion of complex carbohydrates within the oral cavity [2]. Beyond its digestive function, salivary alpha-amylase serves as a robust non-invasive biomarker for the sympathetic-adreno-medullary (SAM) system, reflecting physiological and psychological stress levels [3]. In the context of metabolic health, this enzyme is a therapeutic target for managing postprandial hyperglycemia in conditions like type 2 diabetes and obesity [4]. Pharmacological inhibitors, such as acarbose, and natural compounds like phaseolamin work by binding to the enzyme's active site, thereby slowing the conversion of starch into glucose [4]. This delay in carbohydrate absorption helps prevent rapid spikes in blood sugar levels after meals. However, the use of such inhibitors can lead to gastrointestinal side effects, as undigested starch reaches the large intestine and undergoes bacterial fermentation [2]. Research also suggests that salivary alpha-amylase plays a role in oral health by influencing the colonization of bacteria on tooth surfaces [1].

Other names

Alpha-amylase 1AMY1Ptyalin1,4-alpha-D-glucan glucanohydrolaseSalivary amylase

Competitive inhibition of the alpha-amylase enzyme to delay the hydrolysis of dietary starch into maltose and glucose, thereby reducing postprandial glycemic excursions [4].